Venus Concept Overview
Venus Concept develops medical aesthetic devices with a broad product portfolio of minimally invasive and noninvasive medical aesthetic technologies, reaching over 60 countries and 29 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, and Venus Bliss. Venus Concept's hair restoration division includes NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process, and the ARTAS and ARTAS iX Robotic Hair Restoration Systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms.
Cumulative Funding Raised Over Time ($)
$1.2MFeb 2024
$38.7MJul 2017
$39.5MJun 2025
$62.0MMar 2020
$72.0MMay 2014
$92.0MNov 2015
$113.0MNov 2019
Latest News
growth-positive
Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a leader in medical aesthetic technology, has announced a significant reduction in its outstanding debt through a debt-to-equity exchange with Madryn Asset Management. On September 30, 2025, the company converted $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock, reducing its total debt by 24% to approximately $30.1 million. This move is part of Venus Concepts strategy to optimize its capital structure and support long-term growth and profitability. The partnership with Madryn Asset Management is seen as a crucial step in advancing Venus Concepts transformation plan amidst challenging market conditions.
Investment
growth-positive
Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025
Venus Concept Inc., a leader in medical aesthetic technology, announced the release of its third-quarter financial results for fiscal year 2025, scheduled for November 13, 2025. The company will host a conference call to discuss these results and answer questions. Venus Concept offers a wide range of minimally invasive and non-invasive aesthetic and hair restoration technologies, operating in over 60 countries. The company is backed by several prominent healthcare industry growth equity investors. The announcement is expected to have a growth-positive impact on the company, highlighting its global reach and innovative product portfolio.
growth-positive
VERO1 Proven to Cut Delinquency, Boost Occupancy, and Streamline Leasing Across Multifamily
VERO has announced the nationwide rollout of its centralized resident screening platform, VERO1, which was first introduced in 2023. The platform, developed in partnership with operators like Gables Residential, GoldOller, and Asset Living, has shown significant improvements in reducing delinquency, increasing occupancy, and stabilizing net operating income. VERO1 is designed to address industry-wide challenges such as application fraud and lengthy screening timelines, providing fraud-resistant leasing decisions. Customers like Camden have reported substantial improvements in bad debt, occupancy, and resident satisfaction after deploying VEROs platform. The rollout is expected to benefit both mid-market and enterprise operators nationwide.
Product StageCustomersPartners
growth-negative
Venus Concept Inc (VERO) Q2 2025 Earnings Call Highlights: Strategic Shifts Amidst Economic ...
Venus Concept Inc reported a 15% quarter-over-quarter growth in Q2 2025, driven by strong execution despite a challenging environment. The company experienced a 20% growth in total systems and subscription revenue, indicating robust demand. However, second quarter revenue declined 5% year-over-year, with an 18% decrease in international sales. The company announced a strategic transaction to sell its Venus hair business to Meta Health Group for $20 million, allowing it to focus on its core medical aesthetics business. Despite challenges, the company improved its balance sheet by reducing debt obligations. Gross profit decreased by 20% due to economic uncertainty and supply disruptions, and the company reported a net loss of $11.7 million for Q2 2025.
AcquisitionCustomers
growth-negative
Venus Concept Announces Second Quarter 2025 Financial Results
Venus Concept Inc., a global leader in medical aesthetic technology, reported its financial results for the second quarter of 2025. The company experienced a 5% year-over-year decline in total revenue, though it saw a 15% increase quarter-over-quarter. Despite a GAAP net loss of $11.7 million, the company managed to improve its U.S. revenue by 5% year-over-year. Venus Concept completed several registered direct offerings, raising approximately $3.82 million in total. Additionally, the company sold its Venus Hair business to MHG Co. Ltd for $20 million. The company also exchanged $6.5 million of its subordinated convertible notes for Series Y preferred stock. CEO Rajiv De Silva emphasized the companys focus on managing cash burn and making strategic investments for long-term growth.
PIPEAcquisition
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $113.05M |
| Last funding | $845K |
| Stage | Public |
| Rounds | 8 |
| Investors | 8 |
Team Members
5
Employees: 201-500
Web & Social Links
| Website | www.venusconcept.com/en-us/ |
| Careers | Careers page |
Locations
Bnei Brak St 9, Tel Aviv-Yafo, Israel
HaYozma Street 6, Yokne'am Illit, Israel
235 Yorkland Blvd suite 900, North York, ON M2J 4Y8, Canada
Photos & Videos
3 item(s)
Venus Concept Business
Business models
B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesMedical DevicesAesthetic DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
CommunicationsRadio FrequencyTags (13)
non-invasivepain-freerf-technologydermatologyskin-careanti-agingclinicsmedical-deviceslasersnon-surgicalacneminimally-invasivetreatmentsGeographic Markets
GlobalVenus Concept Financials
$113.05M
Total funding
Undisclosed
Capital raised
$845K
Last funding
Public
Funding stage
8
Total rounds
8
Investors
Cumulative Funding Raised Over Time ($)
$1.2MFeb 2024
$38.7MJul 2017
$39.5MJun 2025
$62.0MMar 2020
$72.0MMay 2014
$92.0MNov 2015
$113.0MNov 2019
Private Equity Funding
PIPE
Jun 2025
$845K
PIPE
Feb 2024
$1.2M
Undisclosed Investor(s)
PIPE
Mar 2020
$22.5M
HealthQuest Capital, EW Healthcare Partners, Secdo Capital
PIPE
Nov 2019
$21M
EW Healthcare Partners (Lead)
,
HealthQuest Capital, Longitude Capital, Madryn Asset, Aperture Venture Partners
Undisclosed Round
Jul 2017
$37.5M
Undisclosed Round
Nov 2015
$20M
Oxford Finance Corporation
Undisclosed Round
May 2014
$10M
Longitude Capital
Public Offering / Exit
POEvent
Nov 2019
Undisclosed
Venus Concept Lifecycle
Cumulative Funding Raised Over Time
$1.2MFeb 2024
$38.7MJul 2017
$39.5MJun 2025
$62.0MMar 2020
$72.0MMay 2014
$92.0MNov 2015
$113.0MNov 2019
All Events
PIPE
Jun 2025
$845K
PIPE
Feb 2024
$1.2M
Undisclosed Investor(s)
PIPE
Mar 2020
$22.5M
HealthQuest Capital, EW Healthcare Partners, Secdo Capital
PIPE
Nov 2019
$21M
EW Healthcare Partners (Lead)
,
HealthQuest Capital, Longitude Capital, Madryn Asset, Aperture Venture Partners
Undisclosed Round
Jul 2017
$37.5M
Undisclosed Round
Nov 2015
$20M
Oxford Finance Corporation
Undisclosed Round
May 2014
$10M
Longitude Capital
POEvent
Nov 2019
Undisclosed
Venus Concept News
97 articles
growth-positive
Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a leader in medical aesthetic technology, has announced a significant reduction in its outstanding debt through a debt-to-equity exchange with Madryn Asset Management. On September 30, 2025, the company converted $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock, reducing its total debt by 24% to approximately $30.1 million. This move is part of Venus Concepts strategy to optimize its capital structure and support long-term growth and profitability. The partnership with Madryn Asset Management is seen as a crucial step in advancing Venus Concepts transformation plan amidst challenging market conditions.
Investment
growth-positive
Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025
Venus Concept Inc., a leader in medical aesthetic technology, announced the release of its third-quarter financial results for fiscal year 2025, scheduled for November 13, 2025. The company will host a conference call to discuss these results and answer questions. Venus Concept offers a wide range of minimally invasive and non-invasive aesthetic and hair restoration technologies, operating in over 60 countries. The company is backed by several prominent healthcare industry growth equity investors. The announcement is expected to have a growth-positive impact on the company, highlighting its global reach and innovative product portfolio.
growth-positive
VERO1 Proven to Cut Delinquency, Boost Occupancy, and Streamline Leasing Across Multifamily
VERO has announced the nationwide rollout of its centralized resident screening platform, VERO1, which was first introduced in 2023. The platform, developed in partnership with operators like Gables Residential, GoldOller, and Asset Living, has shown significant improvements in reducing delinquency, increasing occupancy, and stabilizing net operating income. VERO1 is designed to address industry-wide challenges such as application fraud and lengthy screening timelines, providing fraud-resistant leasing decisions. Customers like Camden have reported substantial improvements in bad debt, occupancy, and resident satisfaction after deploying VEROs platform. The rollout is expected to benefit both mid-market and enterprise operators nationwide.
Product StageCustomersPartners
growth-negative
Venus Concept Inc (VERO) Q2 2025 Earnings Call Highlights: Strategic Shifts Amidst Economic ...
Venus Concept Inc reported a 15% quarter-over-quarter growth in Q2 2025, driven by strong execution despite a challenging environment. The company experienced a 20% growth in total systems and subscription revenue, indicating robust demand. However, second quarter revenue declined 5% year-over-year, with an 18% decrease in international sales. The company announced a strategic transaction to sell its Venus hair business to Meta Health Group for $20 million, allowing it to focus on its core medical aesthetics business. Despite challenges, the company improved its balance sheet by reducing debt obligations. Gross profit decreased by 20% due to economic uncertainty and supply disruptions, and the company reported a net loss of $11.7 million for Q2 2025.
AcquisitionCustomers
growth-negative
Venus Concept Announces Second Quarter 2025 Financial Results
Venus Concept Inc., a global leader in medical aesthetic technology, reported its financial results for the second quarter of 2025. The company experienced a 5% year-over-year decline in total revenue, though it saw a 15% increase quarter-over-quarter. Despite a GAAP net loss of $11.7 million, the company managed to improve its U.S. revenue by 5% year-over-year. Venus Concept completed several registered direct offerings, raising approximately $3.82 million in total. Additionally, the company sold its Venus Hair business to MHG Co. Ltd for $20 million. The company also exchanged $6.5 million of its subordinated convertible notes for Series Y preferred stock. CEO Rajiv De Silva emphasized the companys focus on managing cash burn and making strategic investments for long-term growth.
PIPEAcquisition
growth-negative
Venus Concept: Q2 Earnings Snapshot
Venus Concept Inc., a Toronto-based company specializing in hair transplant devices, reported a significant financial loss in its second quarter. The company experienced a loss of $11.7 million, translating to a per-share loss of $8.03. Despite the loss, the company generated $15.7 million in revenue during the same period. This financial report was generated by Automated Insights using data from Zacks Investment Research.
Neutral
Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025
Venus Concept Inc., a global leader in medical aesthetic technology, announced that it will release its second-quarter financial results for fiscal year 2025 on August 14, 2025. The company will host a conference call to discuss the results and answer questions. Venus Concept offers a wide range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, reaching over 60 countries. The companys product portfolio includes various aesthetic device platforms and hair restoration systems. Venus Concept is supported by several prominent healthcare industry growth equity investors.
growth-positive
Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a leader in medical aesthetic technology, announced a debt-to-equity exchange with Madryn Asset Management, reducing its debt by $6.5 million. This transaction, completed on June 30, 2025, decreases the companys total debt obligations by 14% to $34.3 million. The exchange involved converting subordinated convertible notes into Series Y preferred stock. CEO Rajiv De Silva emphasized the importance of this financial restructuring in optimizing the companys capital structure and supporting its strategic goals, including the divestiture of the Venus Hair business. Madryn Asset Management expressed confidence in Venus Concepts transformation plan and future growth prospects.
Investment
growth-positive
Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a leader in medical aesthetic technology, announced the closing of a registered direct offering priced at-the-market under Nasdaq rules. The offering involved the sale of 434,720 shares of common stock at $2.65 per share, generating approximately $1.15 million in gross proceeds. Additionally, the company issued unregistered short-term warrants to purchase up to 869,440 shares of common stock, potentially bringing in an additional $2.3 million if fully exercised. H.C. Wainwright & Co. acted as the exclusive placement agent. The proceeds will be used for general corporate purposes. The offering was made under a shelf registration statement declared effective by the SEC.
PIPE/PO
growth-positive
Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a leader in medical aesthetic technology, announced a registered direct offering of 434,720 shares of common stock at $2.65 per share, expected to raise approximately $1.15 million. Additionally, the company will issue unregistered short-term warrants for up to 869,440 shares, potentially raising an extra $2.3 million if fully exercised. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The proceeds will be used for general corporate purposes. The offering is expected to close around June 9, 2025, subject to customary conditions.
PIPE/PO
growth-positive
Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million
Venus Concept Inc., a leader in medical aesthetic technology, has entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group for $20 million. This all-cash transaction aims to enhance Venus Concepts financial condition and provide capital for strategic growth initiatives. The sale will allow Venus Concept to focus on its core global medical aesthetics business, improving revenue growth and cash flow. Meta Healthcare Group will acquire the hair restoration technologies ARTAS and NeoGraft, along with related assets, and will assume the manufacturing and R&D facility in San Jose, California. This acquisition aligns with Meta Healthcare Groups strategy to expand its hair loss-related business areas.
Acquisition
growth-negative
Venus Concept Inc (VERO) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines Amid ...
Venus Concept Inc reported a challenging financial performance with a 22% year-over-year decline in total revenue for the first quarter. The company is focusing on transitioning to higher quality cash revenues and managing cash burn through disciplined cost management. Despite the financial setbacks, Venus Concept enhanced its balance sheet by converting $11 million of Madryn debt to equity and securing a new bridge loan amendment. The company plans to launch a new body contouring device in the second half of 2025, aiming for significant market uptake. The global capital equipment environment and economic uncertainties are impacting system adoption and international revenue.
InvestmentProduct Stage
growth-negative
Venus Concept Announces First Quarter 2025 Financial Results
Venus Concept Inc., a leader in medical aesthetic technology, reported a 22% year-over-year decline in total revenue for Q1 2025, amounting to $13.6 million. The company also experienced a GAAP net loss of $12.4 million. Despite these challenges, Venus Concept executed two registered direct offerings, raising approximately $2.67 million in total. The company exchanged $11 million of its convertible notes for preferred stock with Madryn Asset Management. CEO Rajiv De Silva emphasized the companys focus on managing cash burn and targeting sequential revenue growth in Q2. The financial results reflect ongoing market difficulties, but recent equity transactions indicate investor confidence in Venus Concepts long-term potential.
PIPE/POInvestment
growth-positive
Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock
Venus Concept Inc., a leader in medical aesthetic technology, announced the closing of a registered direct offering, raising approximately $2.7 million in total gross proceeds. The offering was priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. The funds will be used for general corporate purposes. Venus Concept offers a wide range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, with a presence in over 60 countries. The company has been supported by prominent healthcare growth equity investors.
PIPE/PO
growth-positive
Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a leader in medical aesthetic technology, announced a registered direct offering of 386,700 shares of common stock at $4.06 per share, expected to raise approximately $1.5 million. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, is set to close around April 14, 2025, pending customary conditions. The proceeds will be used for general corporate purposes. The shares are offered under a shelf registration statement effective since November 1, 2024. Venus Concepts portfolio includes minimally invasive and non-invasive aesthetic and hair restoration technologies, with a presence in over 60 countries.
PIPE/PO
growth-positive
Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a leader in medical aesthetic technology, announced the closing of its registered direct offering, raising approximately $1.1 million. The offering was priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds will be used for general corporate purposes. The offering was made under a shelf registration statement effective since November 1, 2024. Venus Concept offers a broad portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and operates in over 60 countries. The company is backed by several leading healthcare industry growth equity investors.
PIPE
growth-positive
Venus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a leader in medical aesthetic technology, announced a registered direct offering of 328,573 shares of common stock at $3.50 per share, expected to close around April 10, 2025. The offering, managed by H.C. Wainwright & Co., is anticipated to raise approximately $1.1 million in gross proceeds. The funds will be used for general corporate purposes. The offering is conducted under a shelf registration statement effective since November 1, 2024. Venus Concepts portfolio includes minimally invasive and non-invasive aesthetic and hair restoration technologies, and the company operates in over 60 countries.
PIPE/PO
growth-positive
Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025
Venus Concept Inc., a leader in global medical aesthetic technology, announced that it will release its first quarter financial results for fiscal year 2025 on May 15, 2025. The company will host a conference call to discuss the results and answer questions. Venus Concept offers a wide range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies, reaching over 60 countries. The company is backed by prominent healthcare industry growth equity investors. The announcement of the financial results is seen as growth-positive, reflecting the companys ongoing commitment to transparency and engagement with investors.
growth-negative
Venus Concept Inc (VERO) Q4 2024 Earnings Call Highlights: Navigating Challenges and Strategic ...
Venus Concept Inc reported a decline in total revenue by 13% year-over-year, with lease revenue dropping by 58% in Q4. Despite these challenges, cash systems revenue increased by 10%, and cash sales in the US rose by 27%. The company reduced its total debt obligations by 47% and made progress in restructuring its debt. A new management structure aims to streamline decision-making for future growth. However, macroeconomic headwinds and supply-related shortfalls impacted global systems adoption. The company remains cautious about future performance due to ongoing strategic reviews. The Venus hair business, particularly the Venus robot, continues to perform well and drive value.
Management ChangesInvestment
growth-positive
Venus Concept Announces $11 million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a leader in medical aesthetic technology, announced a significant reduction in its outstanding debt by exchanging $11 million of subordinated convertible notes for shares of Series Y preferred stock with Madryn Asset Management. This transaction, completed on March 31, 2025, reduces the companys total debt obligations by 54% compared to the previous year. The move is part of Venus Concepts ongoing efforts to optimize its capital structure, providing greater financial flexibility for sustained growth and profitability. Madryn Asset Management expressed continued support for Venus Concepts transformation plan and future product roadmap.
InvestmentPartners
growth-negative
Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Venus Concept Inc., a leader in medical aesthetic technology, reported its financial results for the year ending December 31, 2024. The company reduced its outstanding debt by 47% and saw a 14% decrease in cash used in operations. Despite these improvements, the company experienced a 13% year-over-year decline in fourth-quarter revenue. Venus Concept expanded its international distributor network and certified products in India. The company executed a 1-for-11 reverse stock split and regained compliance with Nasdaqs listing standards. Additionally, Venus Concept amended its Bridge Loan Agreement with Madryn Health Partners to increase its financing capacity by $10 million. Management remains focused on reducing cash burn and making strategic investments for future growth.
PartnersInvestmentManagement ChangesPublic Trading
growth-positive
Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025
Venus Concept Inc., a global leader in medical aesthetic technology, announced the release of its fourth quarter and fiscal year 2024 financial results, scheduled for March 31, 2025. The company will host a conference call to discuss these results, which will be accessible via phone and webcast. Venus Concept offers a diverse range of minimally invasive and non-invasive aesthetic and hair restoration technologies, reaching over 60 countries. The company is supported by prominent healthcare growth equity investors. The announcement is likely to have a growth-positive impact on the company as it highlights its extensive product portfolio and investor backing.
growth-negative
Venus Concept Announces 1-for-11 Reverse Stock Split
Venus Concept Inc., a global leader in medical aesthetic technology, announced a 1-for-11 reverse stock split of its common stock, effective March 3, 2025. This move aims to increase the bid price of the companys stock to regain compliance with Nasdaq Capital Market listing requirements. The reverse split, approved by stockholders on February 14, 2025, will see every 11 shares reclassified into one new share, without altering the rights or preferences of the shares. The companys stock will continue trading under the symbol VERO with a new CUSIP number. The reverse split will not affect the number of authorized shares or the par value of the common stock, and no fractional shares will be issued.
growth-positive
Venus Concept Announces Senior Management Changes
Venus Concept Inc., a leader in medical aesthetic technology, announced significant changes in its senior leadership team as part of its ongoing transformation efforts. Dr. Hemanth Varghese, President and COO, will depart, and Bill McGrail, EVP, Technical Operations & Compliance, will retire. New appointments include Kirk Gunhus as Chief Revenue Officer, Ross Portaro as EVP, Commercial Strategy and Head of Venus Hair, Melissa Kang as Chief Product Officer, and Michael Mandarello taking on an expanded role as Head of Strategy & Operations. These changes aim to streamline decision-making and position the company for growth and profitability. Venus Concept is backed by leading healthcare investors and offers a broad portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies.
Management Changes
growth-negative
Venus Concept Announces Third Quarter of Fiscal Year 2024 Financial Results
Venus Concept Inc., a leader in medical aesthetic technology, reported its financial results for the third quarter of 2024, revealing a 15% decline in revenue year-over-year, falling short of the estimated $17.0 million. Despite this, the company reduced its cash used in operations by 40% year-over-year and decreased its total debt obligations significantly. The company received regulatory approvals to market its Venus Bliss MAX system in Canada and Australia, which could potentially expand its customer base. However, the CEO noted ongoing challenges in aesthetic capital equipment sales due to macroeconomic headwinds, particularly in the US. The company remains focused on improving cash flow and strengthening its balance sheet for sustainable growth.
Customers
growth-positive
Venus Concept Announces Expansion of International Distribution Network and Certification of Products in India
Venus Concept Inc., a leader in medical aesthetic technology, announced its expansion into international markets through new partnerships and product certifications. The company has partnered with Index International Ltd. in Taiwan, Quirugil S.A in Colombia, and Spectra Medical Systems in India. These partnerships aim to enhance Venus Concepts distribution network and growth in key global markets. The companys products, including Venus ARTAS iX and Venus Legacy, have been certified in India, allowing immediate sales in one of the largest aesthetics markets. CEO Rajiv De Silva emphasized the strategic importance of these developments in evolving the companys commercial strategy outside the U.S. and leveraging partner networks for growth.
Partners
growth-negative
Analysis of Masters Capital Management's Recent Transaction in Venus Concept Inc
On October 1, 2024, Masters Capital Management LLC reduced its holdings in Venus Concept Inc by 85,686 shares, reflecting a strategic adjustment in its investment portfolio. This decision aligns with the firms risk management strategy, given Venus Concepts financial challenges and underwhelming stock performance. The transaction coincided with a 12.03% decline in Venus Concepts stock price, highlighting a negative market reaction. Venus Concept, a medical technology company, has faced significant financial hurdles, with its stock price significantly below its GF Value. The move by Masters Capital Management indicates a scaling back of exposure to Venus Concept, possibly reallocating resources to more promising investments.
Investment
growth-positive
Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024
Venus Concept Inc., a leader in medical aesthetic technology, announced that it will release its third quarter financial results for fiscal year 2024 on November 13, 2024. The company will host a conference call to discuss these results, providing an opportunity for investors and analysts to engage with the management team. Venus Concept operates in over 60 countries, offering a wide range of minimally and non-invasive aesthetic and hair restoration technologies. The company is supported by several prominent healthcare growth equity investors. The announcement is likely to have a growth-positive impact on the company as it highlights its global reach and diverse product offerings.
growth-positive
Venus Concept Announces $15 million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a global leader in medical aesthetic technology, announced a significant reduction in its debt by exchanging $15 million of senior debt held by Madryn Asset Management for 203,583 shares of Series Y preferred stock. This transaction, completed on September 26, 2024, reduces the companys total debt obligations to approximately $34.6 million, down from $46 million as of June 30, 2024, and $74.9 million as of December 31, 2023. CEO Rajiv De Silva highlighted that this move is part of the companys ongoing transformation plan aimed at optimizing its capital structure and achieving long-term profitability. Madryn Asset Management expressed continued support for Venus Concepts growth initiatives.
Investment
growth-positive
Venus Concept Announces Australian Regulatory Approval for Venus Bliss MAX
Venus Concept Inc., a global leader in medical aesthetic technology, announced that it has received clearance from the Therapeutic Goods Administration (TGA) in Australia to market its Venus Bliss MAX system. This flagship platform offers a comprehensive body treatment solution and is already available in select global markets. The Venus Bliss MAX integrates three of Venus Concepts leading technologies for cellulite reduction, muscle conditioning, and fat reduction. The company anticipates strong positive feedback from Australian service providers, mirroring the success seen globally. Venus Concepts extensive product portfolio and backing by prominent healthcare investors position it well for continued growth.
Customers
growth-negative
Venus Concept Announces Second Quarter of Fiscal Year 2024 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, has reported its financial results for Q2 2024. The companys total revenue was $16.6 million, down 17% YoY. However, the gross margin increased by 62 basis points YoY to 71.5%. The company also announced a $35 million debt-to-equity exchange transaction, reducing its debt balance and bringing it back into compliance with the Nasdaq Minimum Equity Requirement. Venus Concept also received a medical device license from Health Canada and entered a strategic partnership with Skin Laundry Holdings, Inc.
InvestmentPartners
growth-positive
Venus Concept Announces Regulatory Approval for Venus Bliss MAX in Canada
Venus Concept Inc., a global medical aesthetic technology leader, has received a medical device license from Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX is a 3-in-1 body shaping solution that was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The companys entry into Canada will provide customers a comprehensive solution to deliver multiple advanced non-invasive body treatments in one system.
CustomersExpand
Neutral
Venus Concept to Release Second Quarter of Fiscal Year 2024 Financial Results on August 13, 2024
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that it will release its financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 13, 2024. The company will host a conference call to discuss the results, which will also be webcast on the investor relations section of the companys website. Venus Concepts product portfolio includes a range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies.
None
growth-positive
Venus Concept Celebrates Successful Completion of its NEXThetics Events Across North America
Venus Concept Inc., a global leader in medical aesthetic technology, has successfully completed its NEXThetics events across several major cities in North America. These events aim to bring together aesthetic leaders and practitioners to learn about Venus Concepts latest technologies and strategies for maximizing profitability. The events have seen a significant increase in popularity and attendance, with thousands of registrants attending the largest gathering to date in Houston, Texas. The company plans to continue expanding these events across the United States.
CustomersPartnersExpand
growth-positive
Venus Concept Announces Exclusive Strategic Supply Arrangement with Skin Laundry
Venus Concept Inc., a global medical aesthetic technology leader, has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings, Inc. The supply arrangement includes an initial order for Venus Viva devices for Skin Laundrys locations across the United States. Skin Laundry plans to perform thousands of skin resurfacing treatments per month using Venus Concept’s proprietary technology. Skin Laundry, founded in 2013 in Los Angeles, has been a leader in the aesthetic industry and has 66 clinics globally.
PartnersExpand
growth-positive
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
Venus Concept Inc., a global leader in medical aesthetic technology, has regained compliance with the Nasdaq Stock Markets equity requirement. The company was previously issued a deficiency notice in May 2023 for falling below the minimum $2.5 million equity required for continued listing. However, after completing a $35 million debt-to-equity transaction in May 2024, Venus Concept has now met the minimum equity requirement. The company will be subject to a mandatory panel monitor through June 2025.
Investment
growth-positive
Venus Concept Announces Approval for Venus Versa Pro in Canada
Venus Concept Inc., a global leader in medical aesthetic technology, has received a medical device license from Health Canada to market its Venus Versa Pro system in Canada. The Venus Versa Pro is a comprehensive aesthetic platform that combines the latest technologies to offer a total skin rejuvenation experience. The company is excited to bring its latest device to the Canadian market and looks forward to customers in Canada experiencing the best in-class skin treatments that the Venus Versa Pro has to offer.
CustomersExpand
growth-positive
Venus Concept Announces $35 million Debt-to-Equity Exchange Transaction
Venus Concept Inc., a global medical aesthetic technology leader, has announced a significant reduction in its debt balance through a debt-to-equity exchange with Madryn Asset Management. The company exchanged $35.0 million of its senior debt for 576,986 shares of newly-created Series Y preferred stock. This transaction reduces the companys debt balance from $76.7 million to approximately $45.4 million and is expected to help the company regain compliance with Nasdaq’s minimum stockholders’ equity listing standard. The companys CEO, Rajiv De Silva, sees this as a significant milestone in their restructuring efforts and a step towards achieving cash flow breakeven in 2025.
Investment
growth-negative
Venus Concept Announces First Quarter of Fiscal Year 2024 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, announced its financial results for Q1 2024. The companys total revenue was $17.5 million, a 15% decrease year-over-year. However, it exceeded the first quarter estimate of at least $16.5 million by 6% or $1.0 million. The company also announced that it received approval for its Venus Versa Pro system and Venus Bliss MAX from Australia and Israel respectively. Additionally, Venus Concepts existing Main Street Lending Program Loan was purchased by Madryn Asset Management, LP for an undisclosed amount.
Investment
growth-positive
Venus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
Venus Concept Inc., a global medical aesthetic technology leader, has announced that its existing Main Street Lending Program Loan (MSLP Loan) was purchased by affiliates of Madryn Asset Management for an undisclosed amount. Following this, Venus Concept and Madryn entered into a Loan and Security Agreement, where Madryn provides up to $5.0 million in debt financing to support Venus Concepts near-term liquidity requirements. This move is part of Venus Concepts ongoing debt restructuring plan and turnaround efforts.
Investment
Neutral
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that it will release its financial results for the first quarter of fiscal year 2024 before the market opens on May 15, 2024. The company will host a conference call to discuss the results, which will also be webcast live on the investor relations section of the companys website. Venus Concepts product portfolio includes a range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company has been backed by leading healthcare industry growth equity investors.
Growth-Positive
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
Venus Concept Inc., a global medical aesthetic technology leader, has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX, which offers three advanced technologies in one platform, was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance. The company plans to expand its direct sales presence in Israel and invest in new innovative products through its local research & development team.
CustomersExpand
Growth-Positive
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that it has received Therapeutic Goods Administration (TGA) clearance in Australia to market the Venus Versa Pro system. The system combines three powerful technologies to offer a total skin rejuvenation experience. The company is looking forward to bringing the Venus Versa Pro system to Australia, a major market where it continues to invest. The system has received positive feedback from customers regarding its multi-modal system capabilities.
CustomersExpand
growth-negative
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, announced its financial results for the three and twelve months ended December 31, 2023. The company reported a decrease in total revenue and an increase in net loss attributable to stockholders. The company has been executing a transformational plan which has resulted in a reduction of cash burn by over 50% compared to the prior year. The company also announced a company-wide rebranding initiative and the commercial launch of its new multi-application platform Venus Versa Pro in the United States. The companys Board of Directors is evaluating potential strategic alternatives to maximize shareholder value.
Management ChangesLayoffs
Growth-Positive
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
Venus Concept Inc. has been granted a request for continued listing on the Nasdaq Capital Market, subject to the company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) or any of the alternative requirements under Nasdaq Listing Rule 5550(b) on or before May 28, 2024. The company had previously received a deficiency notice from Nasdaq for falling below the minimum $2,500,000 equity required for continued listing. Venus Concept is also exploring strategic alternatives to maximize shareholder value and is in dialogue with its existing lenders and investors.
Customers
growth-positive
Venus Concept Launches “NEXThetics” Program
Venus Concept Inc., a global medical aesthetic technology leader, has announced the launch of NEXThetics, a new series of customer education and training events. These events are part of the companys recent Venus Aesthetic Intelligence (Venus AI) rebrand. The NEXThetics events provide professionals in the aesthetics industry a networking opportunity to exchange ideas and share success stories. The company has already hosted several pilot events in Dallas, Miami, Toronto, and Atlanta, which have been well received by customers and industry professionals. The next NEXThetic events will be held in early-June in Cleveland, Ohio and New York City, New York.
CustomersExpand
Growth-Positive
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a global medical aesthetic technology leader, has closed a registered direct offering for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share. In a concurrent private placement, the company issued unregistered warrants to purchase up to 817,748 shares of common stock at an exercise price of $1.34 per share. The gross proceeds from the offering were approximately $1.2 million. The company intends to use the net proceeds for general corporate purposes.
Investment
growth-positive
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Venus Concept Inc., a global medical aesthetic technology leader, has announced definitive agreements for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently, the company will issue unregistered warrants to purchase up to 817,748 shares of common stock at an exercise price of $1.34 per share. The offering is expected to close on or about February 27, 2024. The gross proceeds from the offering are expected to be approximately $1.2 million.
Investment
growth-positive
Venus Concept Announces CE Mark for Venus Versa Pro in Europe
Venus Concept Inc., a global medical aesthetic technology leader, has received the CE Mark from DEKRA Certification B.V. to market the Venus Versa Pro system in the European Union. The system incorporates Venus Concept’s latest advancements in fractional skin resurfacing, enabling enhanced ablation and coagulation to achieve optimal results when treating a wide range of skin conditions. The CE Mark approval follows the commercial launch of the device in the United States in November 2023.
CustomersExpand
Neutral
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that it will release its financial results for the fourth quarter and fiscal year 2023 before the market opens on April 1, 2024. The company will host a conference call to discuss the results and answer questions. Venus Concepts product portfolio includes aesthetic device platforms and hair restoration systems. The company operates in over 60 countries and 12 direct markets and is backed by leading healthcare industry growth equity investors.
Growth-Positive
Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th
Venus Concept Inc., a global leader in medical aesthetic technology, announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference will be held at the Cliff Lodge in Snowbird, UT from February 13th – 14th. The company will participate in virtual investor meetings on Tuesday, February 13th. Venus Concept has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and operates in over 60 countries and 12 direct markets.
Partners
Neutral
Venus Concept Inc. Announces Review of Strategic Alternatives
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. These alternatives may include financings, mergers, reverse mergers, other business combinations, sales of assets, licensings or other transactions. The company has retained Canaccord Genuity LLC as its financial advisor for this process. There is no set timetable for the completion of this process and the company does not intend to disclose developments unless a definitive agreement is executed or the Board determines further disclosure is required.
InvestmentManagement Changes
growth-positive
Venus Concept Inc. Announces Issuance of $2.0M of Convertible Notes
Venus Concept Inc., a global medical aesthetic technology leader, has issued new secured convertible notes to EW Healthcare Partners, L.P. and one of its affiliates in an aggregate principal amount of $2.0 million. The notes, which have a maturity date of December 9, 2025, will provide Venus Concept with additional liquidity to support ongoing operations and execution of its strategic turnaround objectives. The companys CEO, Rajiv De Silva, thanked EW Healthcare for their partnership and support.
Investment
growth-positive
Venus Concept Launches Venus Prime
Venus Concept Inc., a global leader in medical aesthetic technology, has announced the launch of Venus Prime, a structured in-house financing program for new customers in North America. This program replaces the companys previous subscription program and offers competitive financing rates and payment flexibility for customers purchasing their aesthetic medical devices. The program also includes a technology upgrade program for customers in their second and third years of ownership. Venus Prime is available to customers who may not be eligible for financing by traditional third-party lenders but have reputable credit and business practices.
CustomersPartners
growth-positive
Venus Concept Announces New International Distributors in the United Kingdom and India to Continue Global Growth
Venus Concept Inc., a global medical aesthetic technology leader, announced the expansion of its international distributor network with the signing of two new exclusive partnerships with Core Aesthetics Skin & Laser Limited in the United Kingdom and Spectra Medical Systems in India. Both regions are high growth markets for the Company. The execution of these agreements represents an important step towards Venus Concept’s focus of driving international growth through strong distributor partnerships. Core Aesthetics and Spectra will begin their sale, service and training of the Company’s products in their respective regions in January 2024.
PartnersExpand
growth-negative
Venus Concept Announces Third Quarter of Fiscal Year 2023 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, has reported its financial results for Q3 2023, showing a decrease in total revenue by 18% year-over-year to $17.6 million. The company also reported a GAAP net loss attributable to stockholders of $9.1 million, down $5.5 million, or 38% year-over-year. The company has been executing a Transformational Plan which includes restructuring activities and the establishment of a medical advisory board for AI.ME. Venus Concept also announced the promotion of Dr. Hemanth Varghese to the newly created role of President and COO.
Management ChangesLayoffs
growth-positive
Venus Concept Launches Venus Versa Pro, its new multi-application platform for face and body treatments
Venus Concept Inc., a global medical aesthetic technology leader, has announced the commercial launch of its new multi-application platform Venus Versa Pro in the United States. The platform supports 10 different applicators that can be used individually or in combination to target a wide range of aesthetic conditions. The launch of Venus Versa Pro is part of the companys strategic commitment to deliver innovative solutions to its customers. The company expects the Venus Versa Pro to contribute to its revenue growth in 2024 and beyond.
CustomersExpand
Venus Concept Launches New “Venus Aesthetic Intelligence” Branding and Updated “Venus.ai” Website to Reflect New Vision for the Company
growth-positive
Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations
Venus Concept Inc., a global medical aesthetic technology leader, has promoted Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO). Dr. Varghese joined Venus Concept in October of 2022 and has been instrumental in the companys turnaround strategy. In his new role, he will oversee Sales and Marketing, and Technical Operations, among other responsibilities. The company also announced the hiring of Mr. Kirk Gunhus as Vice President & General Manager, International Sales and Marketing.
Management Changes
Neutral
Venus Concept to Release Third Quarter of Fiscal Year 2023 Financial Results on November 14, 2023
Venus Concept Inc., a global leader in medical aesthetic technology, has announced that it will release its financial results for the third quarter of fiscal year 2023 after the market closes on November 14, 2023. The companys management will host a conference call to discuss the results and answer questions. The call will also be webcast live on the investor relations section of the companys website. A replay of the call will be available for two weeks. Venus Concepts product portfolio includes a range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies.
growth-positive
e.l.f. Beauty upgraded, AutoZone downgraded: Wall Street's top analyst calls
Several companies have been upgraded, downgraded, or initiated by various Wall Street analysts. e.l.f. Beauty, Shoals Technologies, Xcel Energy, Frontdoor, and Eaton have been upgraded by Jefferies, Piper Sandler, BofA, Truist, and JPMorgan respectively. AutoZone, LCI Industries, Venus Concept, PTC Therapeutics, and Carrier Global have been downgraded by Oppenheimer, DA Davidson, BTIG, Truist, and JPMorgan respectively. Bernstein, Seaport Research, Oppenheimer, TD Cowen, and Goldman Sachs have initiated coverage on Disney, Roku, ImmunoGen, Block, and Enterprise Products respectively.
CustomersPartners
growth-positive
Venus Concept Inc. Announces Debt Restructuring, Preliminary Third Quarter 2023 Revenue Results and Updates Fiscal Year 2023 Revenue Guidance
Venus Concept Inc., a global medical aesthetic technology leader, has finalized an agreement with its lenders, City National Bank of Florida and Madryn Asset Management, to restructure its existing debt obligations. This will improve the companys overall financial position by deferring certain principal and interest payments under its senior debt and exchanging a portion of its convertible notes for preferred stock. The debt restructuring supports the company’s strategic turnaround efforts, by strengthening its capital structure, improving its liquidity position, and enhancing the path to cashflow breakeven in the second half of 2024.
InvestmentPartners
growth-positive
Venus Concept Receives 510(k) Clearance for the Venus Versa Pro System, Its New Multi-Application Platform
Venus Concept Inc., a global medical aesthetic technology leader, has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Venus Versa Pro System, a new multi-application platform for aesthetic and cosmetic procedures. The system is based on a multi-application approach and offers the most in-demand aesthetic treatments. The company expects the Venus Versa Pro System to contribute significantly to its revenue growth in 2024. The system will provide superior, comprehensive technologies to support existing and future customers, and address the growing demand for multi-modal solutions in aesthetics.
InvestmentCustomers
growth-positive
Venus Concept Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Venus Concept Inc., a global leader in medical aesthetic technology, has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. The conference will be held both virtually and in person at the Lotte New York Palace in New York, NY from September 11th-13th. The companys management will be available for investor meetings and their presentation will be accessible via webcast. Venus Concepts product portfolio includes a range of minimally invasive and non-invasive medical aesthetic and hair restoration technologies.
Investment
growth-positive
12 Best and Cheapest Countries for a Hair Transplant
The article discusses the hair transplant market and highlights the top 12 best and cheapest countries for a hair transplant. It mentions that the hair restoration industry has given rise to a growing sector called wellness tourism where people from various countries travel for hair transplant treatments. The global hair transplant market is projected to reach USD 43.13 billion by 2026. Venus Concept Inc., a company specializing in surgical and non-surgical hair restoration solutions, is mentioned as a standout in the industry. The article also provides a list of the 12 best and cheapest countries for a hair transplant, including Poland, Italy, France, Russia, Malaysia, and Brazil. The rankings are based on cost and quality factors. The date of the event described in the article is not provided.
CustomersPartners
growth-negative
Venus Concept Inc.'s (NASDAQ:VERO) Shares Not Telling The Full Story
The article discusses Venus Concept Inc.s low price-to-sales (P/S) ratio and its impact on shareholders. The companys revenue has been declining, leading to a reduced P/S ratio. The article questions whether the low P/S ratio is justified and examines the companys revenue forecasts. While Venus Concepts forecasted growth is in line with the industry, some shareholders are skeptical and have accepted lower selling prices. The article suggests that the P/S ratio is more indicative of investor sentiment and future expectations rather than a valuation tool. It advises investors to consider the analysts forecasts and potential risks before making investment decisions.
Customers
growth-negative
Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, announced its Q2 2023 financial results, revealing a decrease in total revenue by 26% year-over-year to $20.1 million. The company also reported a GAAP net loss attributable to stockholders of $7.4 million, down 30% year-over-year. Despite the decline, the companys CEO, Rajiv De Silva, stated that the results were in line with the companys expectations and that 2023 is a year of refocusing the business. The company also announced a stock purchase agreement with EW Healthcare Partners for a multi-tranche private placement of senior convertible preferred stock for maximum gross proceeds of up to $9 million.
InvestmentManagement Changes
Growth-Positive
Venus Concept Announces Establishment of Medical Advisory Board For AI.ME™ -Its Next Generation Robotic Platform
Venus Concept Inc., a global medical aesthetic technology leader, has announced the establishment of a medical advisory board for AI.ME, its next-generation robotic platform. The board, composed of six leading physicians, will provide strategic input, guidance, and clinical recommendations for the companys emerging robotic technology. AI.ME, which received its first 510(k) clearance from the U.S. FDA in December 2022, is the first and only robotic system cleared for fractional skin resurfacing. The company expects to begin engaging members of the advisory board to start utilizing AI.ME in the clinical setting in the coming months, with a commercial launch anticipated in the second half of fiscal year 2024.
Partners
growth-negative
Venus Concept Announces First Quarter of Fiscal Year 2023 Financial Results
Venus Concept Inc., a global medical aesthetic technology leader, announced its Q1 2023 financial results, revealing a 22% YoY decrease in total revenue to $20.5 million. The company also reported a GAAP net loss attributable to stockholders of $9.7 million, compared to a loss of $8.6 million the previous year. Venus Concept has implemented a restructuring plan to reduce costs and announced a 1-for-15 reverse stock split. It also entered into a stock purchase agreement with EW Healthcare Partners for a multi-tranche private placement of senior convertible preferred stock for maximum gross proceeds of up to $9 million.
InvestmentManagement Changes
growth-positive
Venus Concept Inc. Announces Multi-Tranche Private Placement of Senior Convertible Preferred Stock for up to $9 Million with EW Healthcare Partners
Venus Concept Inc. has entered into a stock purchase agreement with funds affiliated with EW Healthcare Partners. The agreement allows the company to issue and sell up to $9,000,000 in shares of senior convertible preferred stock. The initial closing of the agreement is expected to occur today, with the investors purchasing 280,899 shares at a price of $7.12 per share. The proceeds from the offering will be used for working capital and general corporate purposes. Canaccord Genuity acted as the exclusive placement agent and financial advisor to the company in the offering. The securities being offered are not registered under the Securities Act and will be sold in a private placement.
Investment
growth-negative
Venus Concept Announces 1-for-15 Reverse Stock Split
Venus Concept Inc. has announced a 1-for-15 reverse stock split of its common stock in order to increase the bid price and regain compliance with the listing requirements of the Nasdaq Capital Market. The reverse stock split will be effective immediately and the companys stock is expected to begin trading on a split-adjusted basis. The purpose of the reverse stock split is to increase the bid price of the common stock. The companys CUSIP number has also changed as a result of the reverse stock split. Fractional shares will be rounded up to the next whole share. Stockholders do not need to take any further action in connection with the reverse stock split.
Public Trading
Venus Concept to Release First Quarter of Fiscal Year 2023 Financial Results on May 15, 2023
Venus Concept Inc. (NASDAQ:VERO) Q4 2022 Earnings Call Transcript
Venus Concept Announces Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Revenue Guidance
Venus Concept Announces the Launch of its latest generation of ARTAS iX, the World’s Most Advanced Robotic Hair Restoration System
Venus Concept to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 27, 2023
Venus Concept Announces Strategic Business Realignment to Accelerate Its Path to Long-Term, Sustainable, Profitability and Reports Preliminary Revenue Results for Fourth Quarter and Fiscal Year 2022
growth-positive
Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
Venus Concept Inc., a global leader in medical aesthetic technology, has received FDA clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing. The AI.ME robotic system uses advanced visualization, machine vision, and AI algorithms to target the dermis in a pre-planned, selective, and predictable manner. The company sees AI.ME as a versatile platform and plans to continue developing it to provide innovative solutions in various areas of medical aesthetics. The clearance brings Venus Concept one step closer to commercializing AI.ME in the U.S., with plans to introduce the first AI.ME systems with Venus Concept’s leading physician partners in 2023.
InvestmentExpand
Growth-Positive
Venus Concept Announces Completion of $6.72 Million Private Placement Financing
Venus Concept Inc., a global medical aesthetic technology leader, has completed a non-brokered private placement of convertible preferred stock and common stock, raising $6.72 million before offering expenses. The funds will be used for working capital and general corporate purposes. The financing was led by the companys existing investors, including EW Healthcare Partners, Masters Special Situations, LLC, and HealthQuest Capital. The companys CEO, Rajiv De Silva, also led the financing. The company is currently undergoing a comprehensive assessment to achieve a profitable and sustainable growth profile, with the implementation of the transformation plan expected to commence in the first quarter of 2023.
Investment
Venus Concept Announces Third Quarter of Fiscal Year 2022 Financial Results
Venus Concept Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer
growth-neutral
Venus Concept Announces Updated Release Date of November 10, 2022 for Third Quarter of Fiscal Year 2022 Financial Results
Venus Concept Inc. is updating the release date for its third quarter financial results. The results will now be released on November 10, 2022. The company will host a conference call to discuss the results and a live webcast will be provided. Venus Concept is a global medical aesthetic technology leader with a broad product portfolio. They focus on a subscription-based business model and have investors such as EW Healthcare Partners, HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Public Trading
growth-positive
Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance
Venus Concept Inc., a global medical aesthetic technology leader, has announced the appointment of Rajiv De Silva as the companys new CEO and board member, effective October 2, 2022. De Silva has a track record of managing companies through various stages of growth and complex turnarounds. The company also announced the departure of Domenic Serafino as CEO and Director. Alongside the leadership change, Venus Concept has withdrawn its previously issued revenue guidance for fiscal year 2022 and expects to deliver total revenue of at least $21 million for Q3 2022.
Management Changes
Time To Worry? Analysts Are Downgrading Their Venus Concept Inc. (NASDAQ:VERO) Outlook
Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance
Venus Concept Inc. (NASDAQ:VERO): Is Breakeven Near?
Venus Concept to Release Second Quarter of Fiscal Year 2022 Financial Results on August 12, 2022
growth-positive
עור זוהר וקורן עם חברת VENUS CONCEPT - סרוגים
ונוס קונספט, a leading international company in the field of aesthetic medicine, presented its advanced aesthetic medical devices at a press conference. The company showcased its latest innovation, the ונוס ורסה device, which combines IPL and RF technologies for skin rejuvenation, anti-aging, body treatments, and hair removal. The device offers more technologies, control, speed, accuracy, and a variety of treatment combinations in one device. The professional participants expressed great interest in the device, which is expected to attract customers in Israel and worldwide.
Customers
growth-positive
Venus Concept Inc. Announces $22.25 Million Equity Financing
Venus Concept Inc. has entered into a definitive agreement for a private placement of shares of its common stock, Series A convertible preferred stock, and warrants. The private placement is expected to result in gross proceeds of approximately $22.25 million. The funds raised will be used for general corporate purposes. The closing of the private placement is subject to certain conditions and is expected to occur on or before March 20, 2020. Stifel is acting as the lead placement agent for the private placement, with BTIG as the co-placement agent.
Investment
growth-positive
Venus Concept Inc. Announces New Regulatory Clearances
Venus Concept Inc. has received CE Mark approval to market Venus Bliss for non-invasive lipolysis and a medical device license from Health Canada to market NeoGraft 2.0 for hair restoration. The Venus Bliss device offers a comprehensive solution to fat reduction and cellulite reduction, while NeoGraft 2.0 is an automated hair transplant device. The company plans to launch both products on a limited basis and expects full commercial launches in the second quarter of 2020. These launches are expected to contribute to the companys growth expectations in 2020 and beyond.
CustomersPartners
growth-positive
Venus Concept to list on Nasdaq after merger
Israeli-Canadian medical aesthetics company Venus Concept is set to complete a merger with Nasdaq-listed Restoration Robotics. The merger will result in Venus Concepts shareholders owning 85% of the merged company, with Venus Concepts management overseeing both companies technologies. As part of the merger, EW Healthcare Partners and other investors will lead a $21 million investment in the merged company. The valuation of the merged company will be $240 million. Venus Concept recently reported $28 million in revenue for the second quarter of 2019, and its guidance for the merged company in 2019 is $130-135 million in revenue.
AcquisitionInvestment
growth-positive
Restoration Robotics® and Venus Concept Provide Merger Update
Venus Concept, a global medical aesthetic technology leader, provided an update on their pending merger with Restoration Robotics. Venus Concept announced its year-end 2018 and first quarter 2019 results, reporting a 15.2% increase in revenue for 2018 and a 15.1% increase in revenue for Q1 2019. The merger between Venus Concept and Restoration Robotics is expected to close in Q3 2019, subject to customary closing conditions and regulatory approvals. Venus Concepts estimated revenue for 2019, after the merger, is expected to be in the range of $130 to $135 million. Venus Concepts product portfolio includes aesthetic device platforms such as Venus Versa, Venus Legacy, and Venus Velocity. The company has been backed by leading healthcare industry growth equity investors. The article does not mention any specific customers or the valuation or acquisition amount.
AcquisitionManagement Changes
growth-positive
Restoration Robotics merging with Venus Concept
Restoration Robotics and Venus Concept have entered into a merger agreement to combine the two companies in an all-stock transaction. Restoration Robotics will own 15% of the combined company, while Venus Concept will own 85%. The merger is expected to close in the third quarter of 2019. EW Healthcare Partners has committed to lead a $21 million equity investment in the combined companys common stock. Other investors include HealthQuest Capital, Madryn Asset Management, Longitude Capital Management, Fred Moll, and Aperture Venture Partners. The merger aims to create a leading player in minimally invasive hair restoration and offer an end-to-end portfolio of solutions in the hair restoration market.
AcquisitionInvestment
growth-positive
Venus Concept launches 2two5™--An exclusive Advertising Agency dedicated to supporting the non-invasive aesthetic industry and announces partnerships with Yelp and Doctor.com
Venus Concept Ltd. has launched 2two5™, an advertising agency exclusively for providers that use Venus Concept® devices. The agency aims to address the demand for trustworthy advertising services in the aesthetic industry. Yelp and Doctor.com have signed on as channel partners, offering enhanced capabilities and customer service to 2two5™ clients. The agency will leverage non-identifiable demographic data to optimize advertising targeting. Venus Concept® is a global medical technology company that develops and delivers aesthetic technologies and related services in a subscription-based business model.
Partners
growth-positive
Canadian-Israeli co Venus Concept raises $37.5m
Venus Concept, a company in esthetic medicine, has raised $37.5 million from unnamed investors. The company has 70 employees and is managed from Israel and Canada. Venus Concepts most unique product is for the treatment of acne scars. The company reported NIS 100 million in revenue in 2013. The dominant figure in Venus Concept is Domenic Serafino. The companys founders are no longer major shareholders, and it is mainly held by US funds.
Investment
growth-positive
Venus Concept Unveils Venus Velocity™, the New Gold Standard for Laser Hair Removal
Venus Concept has announced the U.S. launch of Venus Velocity, a new diode laser for hair removal. The company aims to make hair removal treatments profitable again by offering a more affordable pricing, longer warranty, no disposables, and a unique subscription-based business model. Venus Velocity is also more versatile, faster, and more comfortable than current competitors. The goal is to provide innovative aesthetic solutions for practitioners while prioritizing the needs of patients. Hair removal treatments are in high demand, and Venus Concept aims to capitalize on this market.
Customers
Venus Concept Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 433 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Venus Concept Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515039394 |
| Crunchbase | venus-concept |
| Phone | +97236073524 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-07-02T00:00:00.000Z |
| Created | 2014-08-03T00:00:00.000Z |
| Status detail | Public on NASDAQ on Nov, 2019; |